|
WO2020188470A1
|
|
Calixcrowns and uses thereof
|
|
US2020078321A1
|
|
Methods and compositions for treatment of asthma or parkinson's disease
|
|
KR20200110963A
|
|
A method for screening STING agonist and a immuno-oncology drug for suppressing solid tumor therefrom
|
|
KR20200000597A
|
|
Screening Method for 5-HT2c receptor antagonists
|
|
WO2017065495A2
|
|
Composition for treatment of inflammatory bowel disease and atopic dermatitis
|
|
KR20170043457A
|
|
A composition for treating inflammatory bowel disease and atopic dermatitis
|
|
KR20110099196A
|
|
A method for screening dipeptidyl peptidase iv inhibitor and a dipeptidyl peptidase iv inhibitor therefrom
|
|
KR20110074828A
|
|
A method for screening a compound of inhibiting interaction between beta-amyloid and vegf and beta-amyloid inhibitor thereof
|
|
WO2012133960A1
|
|
Inhibitor for dipeptidyl peptidase iv
|
|
KR20100109885A
|
|
Protein differentially expressed by angiogenin and detecting method thereof
|
|
KR20120006224A
|
|
Compound for inhibiting osteopontin and pharmaceutical composition comprising the same
|
|
KR20110134654A
|
|
Novel method for screening osteopontin inhibitor and osteopontin inhibitor therefrom
|
|
KR20110093298A
|
|
Antibodies specifically binding to ubiquitin-specific processing protease 17
|
|
EP2431738A1
|
|
Method for screening osteopontin inhibitor and inhibitor prepared thereby
|
|
KR20110052914A
|
|
A method for screening dipeptidyl peptidase iv inhibitor and a dipeptidyl peptidase iv inhibitor therefrom
|
|
KR20100135610A
|
|
A method for screening a compound of inhibiting interaction between beta-amyloid and vegf and beta-amyloid inhibitor thereof
|
